Patents Examined by Julie Ha
  • Patent number: 11363822
    Abstract: The present invention is related to a novel plant defense signaling peptide and applications thereof.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: June 21, 2022
    Assignee: Academia Sinica
    Inventors: Yet-Ran Chen, Ying-Lan Chen, Mei-Chun Tseng
  • Patent number: 11365218
    Abstract: Disclosed are a bifunctional peptide having the capability to reduce inflammation and the capability to facilitate differentiation of stem cells into chondrocytes and the use thereof. Advantageously, the bifunctional peptide is useful for the prevention or treatment of arthritis accompanied by inflammation and damage of cartilage tissue due to excellent effects of reducing inflammation and facilitating differentiation of stem cells into chondrocytes, can be easily applied to various surgical regenerative treatments including orthopedic treatments, and can shorten the treatment period.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: June 21, 2022
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
  • Patent number: 11357783
    Abstract: A composition for preventing hair loss and, more specifically, to a compound having a structure in which finasteride and a peptide are linked through a covalent bond and a pharmaceutical composition or a cosmetic composition for preventing hair loss or promoting hair growth comprising the same. The compound having a structure in which finasteride and a peptide are linked through a covalent bond is excellent in physiological activities such as hair loss improvement, hair growth promotion, cell growth promotion, etc., is excellent in stability in water and skin permeation, and thus can be effectively used as a composition for preventing hair loss and promoting hair growth.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 14, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 11357818
    Abstract: A teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.2 is provided. Such a molar ratio will prevent undesirable gel-formation and provide a homogenous suspension, whereby a unique bioavailablity of teverelix is obtained.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: June 14, 2022
    Assignee: Antev Limited
    Inventors: Guy Poland, Francois Boutignon
  • Patent number: 11357822
    Abstract: A method for treating a subject suffering from Alzheimer's disease is provided. The method includes administering to the subject a therapeutically effective amount of lipopolysaccharide-binding protein (LBP). A composition including a therapeutically effective amount of LBP is also provided.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: June 14, 2022
    Assignee: Stellenbosch University
    Inventors: Etheresia Pretorius, Douglas Bruce Kell
  • Patent number: 11352405
    Abstract: The present invention relates to the medical use of specific GLP-1/glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: June 7, 2022
    Assignee: SANOFI
    Inventors: Aimo Kannt, Maximilian Bielohuby, Ralf Elvert, Michael Wagner, Martin Bossart, Torsten Haack, Stephanie Keil, Werner Seiz
  • Patent number: 11351266
    Abstract: A compound comprising a structure in which isotretinoin is linked to a peptide via a covalent bond and an antibiotic, anti-inflammatory, or anti-oxidative pharmaceutical or cosmetic composition comprising the same. A compound having a structure in which isotretinoin is linked to a peptide via a covalent bond according to the present invention exhibits excellent physiological activity such as antibiotic, anti-inflammatory, or anti-oxidative actions, as well as having outstanding properties, such as solubility in water, etc., and thus can find useful applications in various fields including medicines, cosmetics, etc.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: June 7, 2022
    Assignee: Caregen Co., Ltd.
    Inventors: Yong Ji Chung, Eun Mi Kim
  • Patent number: 11351264
    Abstract: This invention is in the field of medicinal pharmacology. In particular, the invention relates to protease activated receptor type 2 (PAR2) modulating compounds (e.g., mimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment of conditions involving PAR2 activity.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 7, 2022
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Scott A. Boitano, Josef Vagner, Theodore J. Price
  • Patent number: 11352406
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 7, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Patent number: 11345899
    Abstract: Genetically modified proteins with uricolytic activity are described. Proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidase are described.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: May 31, 2022
    Assignee: HORIZON THERAPEUTICS USA, INC.
    Inventors: Jacob Hartman, Simona Mendelovitz
  • Patent number: 11344604
    Abstract: Disclosed herein is a method of treating or preventing renal disease in a subject suffering from Alport Syndrome, as well a method of treating or preventing chronic kidney disease. The method comprises administering to a subject in need thereof an effective amount of human apolipoprotein M.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: May 31, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Alessia Fornoni, Sandra Merscher
  • Patent number: 11338018
    Abstract: Pharmaceutical compositions for treating, mitigating or preventing autoimmune diseases and associated conditions are described herein. Methods for fabricating the compositions and using them are also described.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: May 24, 2022
    Assignee: Harrow IP, LLC
    Inventors: Dennis Elias Saadeh, Mark L. Baum
  • Patent number: 11331305
    Abstract: The invention provides compositions for stimulating the formation of one or more extracellular matrix components that contain a lipoaminoacid derivative of the tripeptide carnosine such as N-Octanoyl Carnosine. Also provided are compositions containing N-Octanoyl Carnosine in combination with selected tripeptide and/or tetrapeptides as well as pharmaceutical and/or cosmetic compositions containing such compositions. The invention further provides methods of using the compositions and compositions of the invention to treat, alleviate, and/or ameliorate a symptom, condition, disorder, or disease of the skin or mucosa, wherein the symptom, condition, disorder, or disease is associated with changes in extracellular matrix components.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: May 17, 2022
    Assignee: ANTEIS SA
    Inventor: Frank Dreher
  • Patent number: 11324687
    Abstract: Provided is at least one peptide of formula (I) and its use, where formula (I) is as follows: X-(Xaa1)n-Pro*-(Xaa2)m-Y (I). In formula (I), n=0 and m=1. At the N terminal end of the peptide, X is selected from H, —CO—R1 and —SO2—R1. At the C terminal end of the peptide, Y is selected from OH, OR1, NH2, NHR1 or NR1R2, R1 and R2 being independently selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulphured, with the possibility to have in said group skeleton a O, S and/or N heteroatom. Pro* corresponds to a Proline, an analogue or derivative thereof.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: May 10, 2022
    Inventors: Olivier Peschard, Philippe Mondon
  • Patent number: 11324703
    Abstract: Disclosed herein are surfactant peptide nanostructures wherein the peptides have repeating hydrophobic amino acids in an integer equal to or less than four. The peptide nanostructures are useful for therapeutic applications, including for delivery of drugs and siRNA.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 10, 2022
    Assignee: 3-D Matrix, Ltd.
    Inventors: Eun Seok Gil, Elton Aleksi, Noriaki Matsuda
  • Patent number: 11325943
    Abstract: Disclosed are various crystalline salt forms of L-Phe-D-Arg-L-Phe-L-Lys-NH2.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: May 10, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: Scott M. Duncan
  • Patent number: 11324802
    Abstract: The present invention provides, among other things, improved therapeutic compositions comprising a C3 fusion protein and methods of making and using the same. In particular, the present invention provides improved methods for the treatment of spinal cord injury and other CNS trauma and/or facilitate axon growth or other tissue repair.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: May 10, 2022
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Ricardo Borjas, Mark Fleming, Mei Huang, Mayur Jain, Tapan Sanghvi, Kumkum Saxena, Amaris Torres-Delgado, Ping Yin, Lisa McKerracher, Elizabeth Ryu
  • Patent number: 11312754
    Abstract: A protein hydrolysate composition is provided. The protein hydrolysate composition comprises isolated peptides useful for ameliorating a condition of a subject. Compositions comprising the protein hydrolysate composition are also provided. The compositions may be adapted for oral or topical administration to the subject, and may compose a foodstuff or beverage (e.g. a medical food), a topical composition (e.g. a lotion, cream, etc.), a kit, and the like. A methods of ameliorating the condition of the subject is further provided. The method include administering the protein hydrolysate composition to the subject. The method may be useful in reducing blood pressure, inflammation, reduced immunity, and/or oxidative stress in the subject.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: April 26, 2022
    Assignee: ACCESS BUSINESS GROUP INTERNATIONAL LLC
    Inventors: Rodney A. Velliquette, Eugene Maly
  • Patent number: 11311598
    Abstract: Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: April 26, 2022
    Assignee: Soligenix, Inc.
    Inventors: Oreola Donini, Annett Rozek, Jackson Lee, John North, Michael Abrams
  • Patent number: 11306342
    Abstract: A cell hydrolysate composition, the composition comprising substantially all protein polypeptides and/or polypeptide fragments derived substantially from all the proteins in a cell from an in vitro cell culture.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: April 19, 2022
    Assignee: Avant Meats Company Limited
    Inventors: Po San Mario Chin, Kai Yi Carrie Chan, Chun Hei Poon